Convizin

Convizin Uses, Dosage, Side Effects, Food Interaction and all others data.

Convizin is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Convizin inhibits both isotypes of the vasopressin receptor (V1a and V2).

Convizin is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range by increasing permeability of the renal collecting ducts to water. Vasopressin also causes vasoconstriction through its actions on vascular 1A receptors. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. Convizin's antagonist activity on V1A receptors may also cause splanchnic vasodilation, resulting in possible hypotension or variceal bleeding in patients with cirrhosis. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.

Convizin
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Convizin
Availability	Prescription only
Generic	Conivaptan
Conivaptan Other Names	Conivaptan
Related Drugs	tolvaptan, demeclocycline, Samsca
Weight	20mg
Type	Injection
Formula	C₃₂H₂₆N₄O₂
Weight	Average: 498.5744 Monoisotopic: 498.205576096
Protein binding	99%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Convizin is an antidiuretic hormone inhibitor used to raise serum sodium levels.

For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.

Convizin is also used to associated treatment for these conditions: Euvolemic Hyponatremia, Hypervolemic Hyponatremia

How Convizin works

Convizin is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V_1A and V₂ receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water.

Toxicity

Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.